Mohammed, R. H. A., and E. C. of Rheumatology, "Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt", Rheumatology International , issue doi: 10.1007/s00296-021-04941-0 [, pp. 1-10, 2021.
Mohammed, R. H. A., A. Goyal, and P. Bansal, Hand and Wrist Rheumatoid Arthritis, , 2020.
Mohammed, R. H. H., Rheumatoid Arthritis Other Perspectives towards a Better Practice, , UK, Intechopen, 2020.
Bajwa, S., and R. H. Mohammed, "Type II Hypersensitivity Reaction",, 2020.
Mangoni, A. A., F. Al Okaily, H. Almoallim, S. Al Rashidi, R. H. A. Mohammed, and A. Barbary, "Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature.", BMC rheumatology, vol. 3, pp. 10, 2019. Abstract

Background: Inhibitors of tumor necrosis factor alpha (TNF-α) are current mainstay of therapies for rheumatoid arthritis (RA). The decision when to withdraw TNF-α inhibitors after achieving remission and the incidence of relapse rates with elective discontinuation are both important questions that demand intense survey in these patients. In this meta-analysis we aimed to estimate the magnitude of relapse rate after elective TNF-α inhibitor discontinuation in RA patients with remission.

Methods: Systematic searches of PubMed/MEDLINE, Cochrane Library databases, grey literature (unpublished and ongoing trials) from the WHO International Clinical Trials Registry Platform and the US National Institutes of Health were performed for studies reporting the outcomes of elective discontinuation of TNF-α inhibitor in RA patients after remission. Random-effects models for meta-analyses were conducted on extracted data.

Results: Out of 390 references screened, 16 RCTs were included. Meta-analysis of 1264 patient data revealed a relapse rate of 0.47 (95% CI 0.41-0.54). Sensitivity analysis showed that none of the studies had higher influence on the results.

Conclusions: Almost half of all the RA patients in remission relapse after elective TNF-α inhibitor discontinuation. This information might be useful when considering this management option with individual patients.